GAU 1814

135 DC U.S. PTO
01/12/98

FEE TRANSMITTAL

(Small Entity)

		Complete if Known	
		Application Number	07/402,450
		Filing Date	September 1, 1989
		First Named Inventor	Murakawa
		Group Art Unit	~~1814~~ 1634
		Examiner Name	Escallan
Total Amount of Payment	($)130.00	Attorney Docket Number	2124-154

RECEIVED
97 JAN 28 PM 3:
GROUP 180

METHOD OF PAYMENT (check one)

1. [X]The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to Deposit Account Number 02-2135 in the name of Rothwell, Figg, Ernst & Kurz

   [ ] Charge any Additional Fee Required Under 37 CFR 1.16 and 1.17

   [ ] Charge for the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance

2. [X] Payment Enclosed: Check

FEE CALCULATION

1. FILING FEE

Fee Description	Fee Code	Fee Paid
[ ] Utility Filing Fee	201	395
[ ] Design Filing Fee	206	165
[ ] Plant Filing Fee	207	270
[ ] Reissue Filing Fee	208	395
[ ] Provisional Filing Fee	214	75

SUBTOTAL $

2. CLAIMS

		Fee from Extra		below		Fee Paid
Total Claims	- 20 =		x	$11	=	
Independent Claims	- 3 =		x	41	=	
Multiple Dependent Claims			+	135	=	

SUBTOTAL $

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Fee Description	Fee Code	Fee Paid
[ ] Surcharge - late filing fee or oath	205	65
[ ] Surcharge - late provisional filing fee or cover sheet	227	25
[ ] Non-English specification	139	130
[ ] For filing a request for reexamination	147	2,520
[ ] Requesting publication of SIR prior to Examiner action	112	920
[ ] Requesting publication of SIR after Examiner action	113	1,840*
[ ] Extension for reply within first month	215	55
[ ] Extension for reply within second month	216	200
[ ] Extension for reply within third month	217	475
[ ] Extension for reply within fourth month	218	755
[ ] Extension for reply within fifth month	228	1,030
[ ] Notice of Appeal	219	155
[ ] Filing a brief in support of an appeal	220	155
[ ] Request for Oral Hearing	221	135
[ ] Petition to institute a public use proceeding	138	1,510
[ ] Petition to revive -unavoidable	240	55
[ ] Petition to revive - unintentional	241	660
[ ] Utility issue fee (or reissue)	242	660
[ ] Design issue fee	243	225
[ ] Plant issue fee	244	335
[X] Petitions to the Commissioner	122	130
[ ] Petitons related to provisional applications	123	50
[ ] Submission of Information Disclosure Statement	126	240
[ ] Recording each patent assignment per property (times number of properties)	581	40
[ ] Filing a submission after final rejection (37 CFR .129(a))	246	395
[ ] For each additional invention to be examined (37 CFR 1.129(b))	249	395

Other fee (specify)

[ ]

* Reduced by Basic Filing Fee Paid

SUBTOTAL $

SUBMITTED BY				Complete (if applicable)	
NAME & REG. NUMBER	E. Anthony Figg, Reg. No. 27,195				
SIGNATURE	E. Anthony Figg	DATE	1/9/98	DEPOSIT ACCOUNT USER ID	

understanding of the subject matter sought to be patented. Accordingly, applicants respectfully submit this petition in compliance with the Board's directive. A supplemental declaration of the inventor and a check in the amount of $130.00 to cover the petition fee under 37 C.F.R. § 1.17(i) accompany this petition. The Commissioner is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 02-2135. A duplicate copy of this paper is provided.

At Example V, at page 12 of the application as filed, reference is made to figures 1, 1A and 1B. These figures did not accompany the application as filed on September 1, 1989. On December 5, 1991, Applicants filed an amendment cancelling from the specification the paragraph referring to the three figures. Applicants submit that none of the figures is necessary to an understanding of the application or for support of any claim. Example V describes an experimental procedure in which peripheral blood lymphocyte RNA from an AIDS patient was amplified using two sets of primers. The first set of primers were designated "HIV A" and "HIV B." The second set of primers were T-cell receptor A and B synthetic oligonucleotides. The first two cycles of PCR amplification employed the enzyme, AMV reverse transcriptase. The following 28 rounds of amplification employed the enzyme, Thermus aquaticus DNA polymerase. The amplification products were analyzed by Southern hybridization. The immobilized amplification products were probed with two separate probes. The first was a radiolabelled oligonucleotide designated "HIV C." The second was a T-cell receptor C